A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: The Anglo–Danish–Dutch Study of Intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe) study

Health Technology Assessment

Volumn 20, Issue 64, 2016, Pages 1-86

  Simmons, Rebecca K ^a   Borch Johnsen, Knut ^b,c   Lauritzen, Torsten ^c   Rutten, Guy E H M ^d   Sandbæk, Annelli ^c   Van Den Donk, Maureen ^d   Black, James A ^a   Tao, Libo ^a   Wilson, Edward C F ^a   Davies, Melanie J ^e   Khunti, Kamlesh ^e   Sharp, Stephen J ^a   Wareham, Nicholas J ^a   Griffin, Simon J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HOLBÆK HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ALBUMINURIA; ALL CAUSE MORTALITY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; COST EFFECTIVENESS ANALYSIS; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; HEALTH STATUS; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; KIDNEY FUNCTION; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETINOPATHY; SCREENING; THERAPY EFFECT; WELLBEING; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH BEHAVIOR; LIFESTYLE; MALE; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; ORGANIZATION AND MANAGEMENT; PRIMARY HEALTH CARE; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; UNITED KINGDOM;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCATED HEMOGLOBIN A; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SECONDARY PREVENTION; UNITED KINGDOM;

EID: 85017209373     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta20640     Document Type: Article

References (135)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th edn. Brussels: International Diabetes Federation; 2013.
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012;29:855–62. http://dx.doi.org/10.1111/j.1464-5491.2012.03698.x
3. Campbell SM, Roland MO, Middleton E, Reeves D. Improvements in quality of clinical care in English general practice 1998–2003: longitudinal observational study. BMJ 2005;331:1121. http://dx.doi.org/10.1136/bmj.38632.611123.AE
4. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:299. http://dx.doi.org/10.1136/bmj.39063.689375.55
5. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673–9. http://dx.doi.org/10.1016/S0140-6736(06)69701-8
6. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–9. http://dx.doi.org/10.1016/S0140-6736(08)60766-7
7. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677–86. http://dx.doi.org/10.1016/S0140-6736(09)61457-4
8. Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011;54:300–7. http://dx.doi.org/10.1007/s00125-010-1948-9
9. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabet Endocrinol 2014;2:474–80. http://dx.doi.org/10.1016/S2213-8587(14)70057-9
10. National Screening Committee. Criteria for Appraisals the Viability, Effectiveness and Appropriateness of a Screening Programme. 2010 URL: www.screening.nhs.uk/criteria. 2010 (accessed 19 March 2010).
11. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992;15:815–19. http://dx.doi.org/10.2337/diacare.15.7.815
12. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med 1996;13:337–40. http://dx.doi.org/10.1002/(SICI)1096-9136(199604)13:4<337::AID-DIA71>3.0.CO;2-A2.
13. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163–9. http://dx.doi.org/10.2337/diacare.20.2.163
14. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ. How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia 2012;55:1651–9. http://dx.doi.org/10.1007/s00125-011-2441-9
15. Goyder EC, McNally PG, Drucquer M, Spiers N, Botha JL. Shifting of care for diabetes from secondary to primary care, 1990–5: review of general practices. BMJ 1998;316:1505–6. http://dx.doi.org/10.1136/bmj.316.7143.1505
16. Plantinga LC, Crews DC, Coresh J, Miller ER, Saran R, Yee J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010;5:673–82. http://dx.doi.org/10.2215/CJN.07891109
17. Flores-Le Roux JA, Comin J, Pedro-Botet J, Benaiges D, Puig-de Dou J, Chillarón JJ, et al. Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study. Cardiovasc Diabetol 2011;10:39. http://dx.doi.org/10.1186/1475-2840-10-39
18. Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn screening study. Diabetes Care 2003;26:2604–8. http://dx.doi.org/10.2337/diacare.26.9.2604
19. Simmons RK, Echouffo-Tcheugui JB, Griffin SJ. Screening for type 2 diabetes: an update of the evidence. Diabetes Obes Metab 2010;12:838–44. http://dx.doi.org/10.1111/j.1463-1326.2010.01244.x
20. Kuo HS, Chang HJ, Chou P, Teng L, Chen TH. A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 1999;28:233–40. http://dx.doi.org/10.1093/ije/28.2.233
21. Chang HJ, Kuo HS, Tung TH, Chou P, Chen TH. Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan. Prev Med 2000;31:396–402. http://dx.doi.org/10.1006/pmed.2000.0728
22. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365–74. http://dx.doi.org/10.1016/S0140-6736(09)62162-0
23. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012;380:1741–8. http://dx.doi.org/10.1016/S0140-6736(12)61422-6
24. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53. http://dx.doi.org/10.1016/S0140-6736(98)07019-6
25. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–17. http://dx.doi.org/10.1016/0168-8227(95)01064-K
26. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–13. http://dx.doi.org/10.1136/bmj.317.7160.703
27. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96. http://dx.doi.org/10.1016/S0140-6736(04)16895-5
28. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial. Lancet 2003;361:2005–16. http://dx.doi.org/10.1016/S0140-6736(03)13636-7
29. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93. http://dx.doi.org/10.1056/NEJMoa021778
30. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829–40. http://dx.doi.org/10.1016/S0140-6736(07)61303-8
31. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–63. http://dx.doi.org/10.1007/s001250051594
32. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–32. http://dx.doi.org/10.1046/j.1523-1755.2003.00712.x
33. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–91. http://dx.doi.org/10.1056/NEJMoa0706245
34. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Int Med 2011;154:554–9. http://dx.doi.org/10.7326/0003-4819-154-8-201104190-00007
35. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765–72. http://dx.doi.org/10.1016/S0140-6736(09)60697-8
36. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabetic Med 2005;22:1379–85. http://dx.doi.org/10.1111/j.1464-5491.2005.01644.x
37. Black N. Patient reported outcome measures could help transform healthcare. BMJ 2013;346:f167. http://dx.doi.org/10.1136/bmj.f167
38. Darzi A. Quality and the NHS next stage review. Lancet 2008;371:1563–4. http://dx.doi.org/10.1016/S0140-6736(08)60672-8
39. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care 1999;22:1125–36. http://dx.doi.org/10.2337/diacare.22.7.1125
40. Anderson RT, Narayan KM, Feeney P, Goff D Jr, Ali MK, Simmons D, et al. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care 2011;34:807–12. http://dx.doi.org/10.2337/dc10-1926
41. Department of Health. Putting Prevention First. Vascular Checks: Risk Assessment and Management. London: Department of Health; 2008.
42. van den Donk M, Sandbæk A, Borch-Johnsen K, Lauritzen T, Simmons RK, Wareham NJ, et al. Screening for type 2 diabetes. Lessons from the ADDITION-Europe study. Diabetic Med 2011;28:1416–24. http://dx.doi.org/10.1111/j.1464-5491.2011.03365.x
43. Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT, et al. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabet Med 2010;27:995–1003. http://dx.doi.org/10.1111/j.1464-5491.2010.03056.x
44. Dalsgaard EM, Christensen JO, Skriver MV, Borch-Johnsen K, Lauritzen T, Sandbæk A. Comparison of different stepwise screening strategies for type 2 diabetes: finding from Danish general practice, Addition-DK. Primary Care Diabetes 2010;4:223–29. http://dx.doi.org/10.1016/j.pcd.2010.06.003
45. Dalsgaard EM, Lauritzen T, Christiansen T, Mai KS, Borch-Johnsen K, Sandbæk A. Socioeconomic factors related to attendance at a type 2 diabetes screening programme. Diabet Med 2009;26:518–25. http://dx.doi.org/10.1111/j.1464-5491.2009.02715.x
46. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Low yield of population-based screening for type 2 diabetes in the Netherlands: the ADDITION Netherlands study. Fam Pract 2007;24:555–61. http://dx.doi.org/10.1093/fampra/cmm052
47. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24(Suppl. 3):6–11. http://dx.doi.org/10.1038/sj.ijo.0801420
48. Webb DR, Khunti K, Srinivasan B, Gray LJ, Taub N, Campbell S, et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials 2010;11:16. http://dx.doi.org/10.1186/1745-6215-11-16
49. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009;59:43–8. http://dx.doi.org/10.3399/bjgp09X394851
50. Sandbæk A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008;51:1127–34. http://dx.doi.org/10.1007/s00125-008-1013-0
51. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res 2000;16:164–71. http://dx.doi.org/10.1002/1520-7560(200005/06)16:3<164::AID-DMRR103>3.0.CO;2-R
52. Glumer C, Carstensen B, Sandbæk A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004;27:727–33. http://dx.doi.org/10.2337/diacare.27.3.727
53. Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008;336:491–5. http://dx.doi.org/10.1136/bmj.39474.922025.BE
54. Ruige JB, de Neeling JN, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 1997;20:491–6. http://dx.doi.org/10.2337/diacare.20.4.491
55. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:156–67. http://dx.doi.org/10.1016/S0140-6736(11)60698-3
56. World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva: WHO; 1999.
57. Echouffo-Tcheugui JB, Simmons RK, Williams KM, Barling RS, Prevost AT, Kinmonth AL, et al. The ADDITION-Cambridge trial protocol: a cluster –randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009;9:136. http://dx.doi.org/10.1186/1471-2458-9-136
58. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253–9. http://dx.doi.org/10.1016/S0140-6736(99)12323-7
59. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614–20. http://dx.doi.org/10.2337/diacare.20.4.614
60. Royal College of General Practitioners in Denmark. Type 2 Diabetes in General Practice –Diagnosis and Treatment. Copenhagen: Royal College of General Practitioners; 1999.
61. McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A, et al. Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Glucose. Sheffield: ScHARR, University of Sheffield; 2001.
62. Rutten GEHM, Verhoeven S, Heine RJ, De Grauw WJC, Cromme PVM, Reenders K. Dutch College of General Practitioners. Practice guideline diabetes mellitus type 2. Huisarts Wetensch 1999;42:67–84.
63. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes: The Management of Type 2 Diabetes. London: NICE; 2009.
64. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70. http://dx.doi.org/10.7326/0003-4819-130-6-199903160-00002
65. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98:823–33. http://dx.doi.org/10.1016/S0161-6420(13)38014-2
66. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281–9. http://dx.doi.org/10.2337/diacare.17.11.1281
67. Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, et al. Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. Curr Med Res Opin 2007;23:2035–42. http://dx.doi.org/10.1185/030079907X210516
68. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108. http://dx.doi.org/10.1097/00005650-199711000-00002
69. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72. http://dx.doi.org/10.1016/0168-8510(96)00822-6
70. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey. Manual and Interpretation Guide. Boston, MA: New England Medical Centre, the Health Institute; 1993.
71. Pouwer F, van der Ploeg HM, Ader HJ, Heine RJ, Snoek FJ. The 12-item well-being questionnaire. An evaluation of its validity and reliability in Dutch people with diabetes. Diabetes Care 1999;22:2004–10. http://dx.doi.org/10.2337/diacare.22.12.2004
72. Pouwer F, Snoek FJ, van der Ploeg HM, Ader HJ, Heine RJ. The well-being questionnaire: evidence for a three-factor structure with 12 items (W-BQ12). Psychol Med 2000;30:455–62. http://dx.doi.org/10.1017/S0033291700001719
73. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999;8:79–91. http://dx.doi.org/10.1023/A:1026485130100
74. Bradley C. Handbook of Psychology and Diabetes: a Guide to Psychological Measurements in Diabetes Research and Practice. Chur: Harwood Academic Press; 1994.
75. Coleman R, Stevens R, Holman R. Updated UKPDS risk engine that estimates primary and secondary cardiovascular disease risk in people with recently-diagnosed or established type 2 diabetes. Diabetes 2012;61(Suppl. 1):103.
76. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. Stat Med 2005;24:993–1007. http://dx.doi.org/10.1002/sim.1981
77. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695–706. http://dx.doi.org/10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
78. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006;59:1087–91. http://dx.doi.org/10.1016/j.jclinepi.2006.01.014
79. Park P, Simmons RK, Prevost AT, Griffin SJ. Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice. BMC Public Health 2008;8:350. http://dx.doi.org/10.1186/1471-2458-8-350
80. Eborall H, Davies R, Kinmonth AL, Griffin S, Lawton J. Patients’ experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007;335:490–3. http://dx.doi.org/10.1136/bmj.39308.392176.BE
81. Graffy J, Grant J, Williams K, Cohn S, Macbay S, Griffin S, et al. More than measurement: practice team experiences of screening for type 2 diabetes. Fam Pract 2010;27:386–94. http://dx.doi.org/10.1093/fampra/cmq022
82. Black JA, Sharp SJ, Wareham NJ, Sandbæk A, Rutten GE, Lauritzen T, et al. Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial. Diabet Med 2014;31:647–56. http://dx.doi.org/10.1111/dme.12410
83. Sandbæk A, Griffin SJ, Sharp SJ, Simmons RK, Borch-Johnsen K, Rutten GE, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomised controlled trial: the ADDITION-Europe study. Diabetes Care 2014;37:2015–23. http://dx.doi.org/10.2337/dc13-1544
84. van den Donk M, Griffin SJ, Stellato RK, Simmons RK, Sandbæk A, Lauritzen T, et al. Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial. Diabetologia 2013;56:2367–77. http://dx.doi.org/10.1007/s00125-013-3011-0
85. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747–59. http://dx.doi.org/10.1007/s00125-004-1527-z
86. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877–90. http://dx.doi.org/10.1007/BF00400195
87. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med 2005;22:554–62. http://dx.doi.org/10.1111/j.1464-5491.2005.01494.x
88. Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, et al. Performance of the UK Prospective Diabetes Study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetes Care 2009;32:708–13. http://dx.doi.org/10.2337/dc08-1918
89. McEwan P, Bergenheim K, Currie C. External validation of the UKPDS outcomes model equations (UKPDS 68) and the UKPDS risk engine equations (UKPDS 56 and 60) in forecasting cardiovascular outcomes in people with type 2 diabetes. Value Health 2006;9:A37–8. http://dx.doi.org/10.1016/S1098-3015(10)64421-X
90. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med 1991;10:585–98. http://dx.doi.org/10.1002/sim.4780100410
91. Lee KJ, Carlin JB. Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation. Am J Epidemiol 2010;171:624–32. http://dx.doi.org/10.1093/aje/kwp425
92. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ: Wiley; 2004.
93. van Dieren S, Peelen LM, Nöthlings U, van der Schouw YT, Rutten GE, Spijkerman AM, et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia 2011;54:264–70. http://dx.doi.org/10.1007/s00125-010-1960-0
94. Jones RH. Bayesian information criterion for longitudinal and clustered data. Stat Med 2011;30:3050–6. http://dx.doi.org/10.1002/sim.4323
95. Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, editors. Developing a Protocol for Observational Comparative Effectiveness Research: A User’s Guide. AHRQ Publication No. 12(13)-EHC 099. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
96. Tao L, Wilson EC, Griffin SJ, Simmons RK, ADDITION-Europe study team. Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITIONEurope trial cohort. Value Health 2013;16:1074–80. http://dx.doi.org/10.1016/j.jval.2013.06.001
97. Curtis L. PSSRU Inflation Indices, Secondary PSSRU Inflation Indices. Canterbury: Personal Social Services Research Unit (PSSRU), University of Kent; 2004.
98. Curtis L. Unit Costs of Health and Social Care 2010. Canterbury: Personal Social Services Research Unit (PSSRU), University of Kent; 2010.
99. Tao L, Wilson EC, Wareham NJ, Sandbæk A, Rutten GE, Lauritzen T, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet Med 2015;32:907–19. http://dx.doi.org/10.1111/dme.12711
100. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS study no. 65). Diabet Med 2003;20:442–50. http://dx.doi.org/10.1046/j.1464-5491.2003.00972.x
101. Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008;10(Suppl. 1):43–55. http://dx.doi.org/10.1111/j.1463-1326.2008.00886.x
102. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340–9. http://dx.doi.org/10.1177/027298902400448902
103. Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, et al. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med 2007;24:982–1002. http://dx.doi.org/10.1111/j.1464-5491.2007.02188.x
104. Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Dordrecht: Springer; 2007. http://dx.doi.org/10.1007/1-4020-5511-0
105. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. URL: www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf (accessed 30 June 2014).
106. Yuan Y. Multiple imputation using SAS software. J Stat Softw 2011;45:1–25. http://dx.doi.org/10.18637/jss.v045.i06
107. Efron B. The bootstrap and Markov chain Monte Carlo. J Biopharm Stat 2011;21:1052–62. http://dx.doi.org/10.1080/10543406.2011.607736
108. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106–8. http://dx.doi.org/10.1192/bjp.187.2.106
109. Eschenbach TG. Technical note: constructing tornado diagrams with spreadsheets. Eng Econ 2006;51:195–204. http://dx.doi.org/10.1080/00137910600695676
110. UK Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249–58. http://dx.doi.org/10.2337/diab.44.11.1249
111. Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001;323:970–5. http://dx.doi.org/10.1136/bmj.323.7319.970
112. Royal College of General Practitioners in Denmark. Type 2 Diabetes in General Practice –An Evidence Based Guideline. Copenhagen: Royal College of General Practitioners in Denmark; 2004.
113. Rutten GEHM, de Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, van der Does FEE. Dutch guidelines on type 2 diabetes mellitus. Dutch College of General Practitioners. Huisarts Wetensch 2006;49:137–52.
114. Doran T, Fullwood C, Gravelle H, Reeves D, Kontopantelis E, Hiroeh U, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med 2006;355:375–84. http://dx.doi.org/10.1056/NEJMsa055505
115. Andrews RC, Cooper AR, Montgomery AA, Norcross AJ, Peters TJ, Sharp DJ, et al. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. Lancet 2011;378:29–39. http://dx.doi.org/10.1016/s0140-6736(11)60442-x
116. Spijkerman AM, Dekker JM, Nijpels G, Jager A, Kostense PJ, van Hinsbergh VW, et al. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study. Eur J Clin Invest 2002;32:924–30. http://dx.doi.org/10.1046/j.1365-2362.2002.01090.x
117. Carstensen B, Kristensen J, Ottosen P, Borch-Johnsen K. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 2008;51:2187–96. http://dx.doi.org/10.1007/s00125-008-1156-z
118. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–39. http://dx.doi.org/10.1056/NEJMoa0808431
119. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59. http://dx.doi.org/10.1056/NEJMoa0802743
120. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72. http://dx.doi.org/10.1056/NEJMoa0802987
121. Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med 2012;29:937–44. http://dx.doi.org/10.1111/j.1464-5491.2012.03644.x
122. Rahman M, Griffin SJ, Rathmann W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. Diabet Med 2003;20:368–74. http://dx.doi.org/10.1046/j.1464-5491.2003.00931.x
123. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458–63. http://dx.doi.org/10.2337/diacare.25.3.458
124. Cleveringa FG, Minkman MH, Gorter KJ, van den Donk M, Rutten GE. Diabetes Care Protocol: effects on patient-important outcomes. A cluster randomized, non-inferiority trial in primary care. Diabet Med 2010;27:442–50. http://dx.doi.org/10.1111/j.1464-5491.2010.02968.x
125. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007;30:1292–3. http://dx.doi.org/10.2337/dc06-1358
126. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–5. http://dx.doi.org/10.1001/jama.285.18.2370
127. Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University Press; 2005.
128. Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell MJ, et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ 2010;341:c4093. http://dx.doi.org/10.1136/bmj.c4093
129. Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300–4. http://dx.doi.org/10.2337/diacare.26.8.2300
130. Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. Value Health 2014;17:462–70. http://dx.doi.org/10.1016/j.jval.2014.03.003
131. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89. http://dx.doi.org/10.1056/NEJMoa0806470
132. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565–76. http://dx.doi.org/10.1056/NEJMoa0806359
133. Kengne AP, Patel A, Colagiuri S, Heller S, Hamet P, Marre M, et al. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 2010;53:821–31. http://dx.doi.org/10.1007/s00125-010-1681-4
134. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:d6898. http://dx.doi.org/10.1136/bmj.d6898
135. Lauritzen T, Sandbæk A, Carlsen AH, Borch-Johnsen K. All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, Denmark. Prim Care Diabetes 2012;6:193–200. http://dx.doi.org/10.1016/j.pcd.2012.04.005